plus
plus

Zetacolest plus 180/10 mg

Pharmaceutical

Product Details:

Leaflet

Composition:

ZETACOLEST PLUS tablets, for oral use, contains:

Each film coated tablet contains:

First layer:

• The active ingredient is bempedoic acid 180 mg.

Second layer:

• The active ingredient is ezetimibe.

 

 Indications and usage:

 

ZETACOLEST PLUS, a combination of bempedoic acid and ezetimibe, is indicated:

 As an adjunct to diet, alone or in combination with other low-density lipoprotein

cholesterol (LDL-C) lowering therapies, to reduce LDL-C in adults with primary

hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).

The bempedoic acid component of ZETACOLEST PLUS is indicated:

 To reduce the risk of myocardial infarction and coronary revascularization in adults who

are unable to take recommended statin therapy (including those not taking a statin) with:

o established cardiovascular disease (CVD), or o a high risk for a CVD event but without established CVD

 

How supplied / storage and handling

 

Pack: Carton box containing (Al\Al) strip each of 10 film coated tablet + leaflet Insert.

For number of strips see outer pack